Ovarian Neoplasms
📧 Sign up to get email alerts when something new happens for Ovarian Neoplasms.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2024-10-31Clinical Trial Update: Study of Maplirpacept (PF-07901801) in Combination With PLD in Patients With Platinum-Resistant Ovarian Cancer [Phase 1, Phase 2]
A Phase 1/2 trial of Maplirpacept in combination with pegylated liposomal doxorubicin for platinum-resistant ovarian cancer was terminated, …
-
CLINICAL_TRIALS research · 2024-07-30Clinical Trial Update: Research and Application of Ultrasonic Intelligent Diagnosis System for Ovarian Mass
This clinical trial update covers research and development of an ultrasonic intelligent diagnosis system for evaluating ovarian masses, with…
-
CLINICAL_TRIALS research · 2024-07-15Clinical Trial Update: Characterization of Ovarian Masses Unable to Classify With Gynecological Ultrasonography: Value of Pelvic MRI With Perfusion- and Diffusion-weighted Imaging
An imaging study evaluating whether pelvic MRI with perfusion- and diffusion-weighted imaging can help characterize undetermined ovarian mas…
-
EMA withdrawal · 2024-03-06EMA Withdrawn: Apealea (paclitaxel) — Inceptua AB
EMA withdrawal of Apealea (paclitaxel) by Inceptua AB for ovarian neoplasms.
-
CLINICAL_TRIALS trial_result · 2023-04-25Clinical Trial Update: TC or BEP in Treating Patients With Ovarian Malignant Sex Cord-Stromal Tumors [Phase 3]
Phase 3 clinical trial investigating TC or BEP chemotherapy regimens for ovarian malignant sex cord-stromal tumors; currently recruiting.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2023-04-25Clinical Trial Update: TC or BEP in Treating Patients With Malignant Ovarian Germ Cell Tumors [Phase 3]
Phase 3 clinical trial evaluating TC or BEP chemotherapy in patients with malignant ovarian germ cell tumors is currently recruiting.
-
CLINICAL_TRIALS trial_result · 2023-03-14Clinical Trial Update: Anti-programmed Cell Death-1 Ligand 1 (aPDL-1) Antibody Atezolizumab, Bevacizumab and Acetylsalicylic Acid in Recurrent Platinum Resistant Ovarian Cancer [Phase 2]
Phase 2 trial evaluating atezolizumab, bevacizumab, and acetylsalicylic acid in recurrent platinum-resistant ovarian cancer has been complet…
-
CLINICAL_TRIALS trial_result · 2022-09-10Clinical Trial Update: Study to Evaluate the Efficacy and Safety of the Combination of Niraparib and Dostarlimab (TSR-042) in Participants With Platinum Resistant Ovarian Cancer [Phase 2]
Phase 2 trial assessing niraparib combined with dostarlimab (TSR-042) in platinum-resistant ovarian cancer; study terminated with posted res…
-
CLINICAL_TRIALS trial_result · 2022-06-13Clinical Trial Update: Use of Regorafenib in Recurrent Epithelial Ovarian Cancer [Phase 2]
Phase 2 trial update evaluating regorafenib in recurrent epithelial ovarian cancer has completed.
-
CLINICAL_TRIALS trial_result · 2022-05-04Clinical Trial Update: Phase II Study DCVAC/OvCa Added to First Line Carboplatin and Paclitaxel Newly Diagnosed Epithelial Ovarian Carcinoma [Phase 2]
Phase II study updating on adding DCVAC/OvCa to first-line carboplatin and paclitaxel for newly diagnosed epithelial ovarian cancer (Phase 2…
-
CLINICAL_TRIALS trial_result · 2022-02-17Clinical Trial Update: Treat of Functional Ovarian Cysts by Compare Between Cocs and Progesterone Only Pills [Phase 3]
A Phase 3 clinical trial comparing COCs versus progesterone-only pills for treating functional ovarian cysts is ongoing or not yet updated i…
-
EMA withdrawal · 2021-11-25EMA Withdrawn: Equidacent (bevacizumab) — Centus Biotherapeutics Europe Limited
Equidacent (bevacizumab) has been withdrawn from the market in the European Medicines Agency record.
-
CLINICAL_TRIALS trial_result · 2021-09-08Clinical Trial Update: Immunohistochemical Evaluation of Protein P16 Expression in Ovarian Germ Cell Tumors.
Completed clinical trial evaluating immunohistochemical P16 expression in ovarian germ cell tumors, with results posted.
-
CLINICAL_TRIALS trial_result · 2021-08-25Clinical Trial Update: Trial on Trabectedin (ET-743) vs Clinician's Choice Chemotherapy in Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancers of BRCA Mutated or BRCAness Phenotype Patients [Phase 3]
Phase 3 trial comparing trabectedin (ET-743) to clinician's choice chemotherapy in recurrent ovarian, primary peritoneal, or fallopian tube …
-
CLINICAL_TRIALS trial_result · 2021-04-08Clinical Trial Update: ZK-Epo Given With Carboplatin in Patients With Recurrent Ovarian Cancer [Phase 2]
Phase 2 clinical trial update of ZK-Epo in combination with carboplatin for recurrent ovarian cancer has completed.
-
CLINICAL_TRIALS trial_result · 2021-01-20Clinical Trial Update: Compare Fallopian Tube Cells Collected by Cytuity With Removed Ovarian/Tubal Tissue to Determine Presence of Malignancy
Clinical trial evaluating whether fallopian tube cells collected by Cytuity can determine the presence of malignancy compared with removed o…
-
CLINICAL_TRIALS trial_result · 2020-11-16Clinical Trial Update: Pharmacokinetic and Safety Study of Niraparib With Normal or Moderate Hepatic Impairment Patients [Phase 1]
Phase 1 pharmacokinetic and safety study of niraparib in patients with normal or moderate hepatic impairment has completed with results post…
-
CLINICAL_TRIALS trial_result · 2020-11-10Clinical Trial Update: Efficacy and Safety of Niraparib Combined With Bevacizumab in Platinum Refractory/Resistant Recurrent Ovarian Cancer [Phase 2]
Phase 2 trial evaluating niraparib in combination with bevacizumab for platinum-refractory/resistant recurrent ovarian cancer; efficacy and …
-
CLINICAL_TRIALS trial_result · 2020-09-22Clinical Trial Update: Efficacy and Safety Study of Pembrolizumab (MK-3475) in Participants With Advanced Recurrent Ovarian Cancer (MK-3475-100/KEYNOTE-100) [Phase 2]
Phase 2 study evaluating pembrolizumab in advanced recurrent ovarian cancer has completed with posted results.
-
CLINICAL_TRIALS trial_result · 2020-09-14Clinical Trial Update: A Controlled Study of the Effectiveness of Oregovomab (Antibody) Plus Chemotherapy in Advanced Ovarian Cancer [Phase 2]
Phase 2 trial evaluating the effectiveness of oregovomab plus chemotherapy in advanced ovarian cancer has completed.
-
CLINICAL_TRIALS trial_result · 2020-08-27Clinical Trial Update: A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients [Phase 3]
Phase III trial comparing niraparib to physician's choice in HER2-negative, germline BRCA mutation–positive breast cancer terminated; result…
-
EMA withdrawal · 2020-07-27EMA Application withdrawn: Doxorubicin Hydrochloride Tillomed (doxorubicin hydrochloride) — Laboratorios Tillomed Spain S.L.U
The EMA withdrew the application for doxorubicin hydrochloride from Laboratorios Tillomed Spain S.L.U. for several cancer indications includ…
-
CLINICAL_TRIALS trial_result · 2020-04-09Clinical Trial Update: A Study of Niraparib in Patients With Ovarian Cancer Who Have Received Three or Four Previous Chemotherapy Regimens [Phase 2]
Phase 2 clinical trial evaluating niraparib in ovarian cancer patients who had three or four prior chemotherapy regimens; study completed wi…
-
CLINICAL_TRIALS trial_result · 2019-09-19Clinical Trial Update: A Phase I Clinical Study With Investigational Compound LTT462 in Adult Patients With Specific Advanced Cancers. [Phase 1]
Phase I trial update for investigational compound LTT462 in adults with advanced cancers; trial terminated with results posted.
-
CLINICAL_TRIALS trial_result · 2019-09-12Clinical Trial Update: Safety and Effectivity Immunotherapy to Treat Ovarian Cancer With Cancer Stem Cells Vaccine [Phase 1, Phase 2]
Clinical trial update on an immunotherapy approach with a cancer stem cell vaccine for ovarian neoplasms, completed Phase 1 and Phase 2.